Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report.


Journal

World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544

Informations de publication

Date de publication:
26 Dec 2019
Historique:
received: 20 09 2019
accepted: 17 12 2019
entrez: 28 12 2019
pubmed: 28 12 2019
medline: 30 5 2020
Statut: epublish

Résumé

Advanced hepatocellular carcinoma (HCC) with macrovascular invasion has an extremely dismal prognosis. We report a rare case of multiple HCC with tumor thrombosis in the portal vein and inferior vena cava that was initially treated with hepatic arterial infusion chemotherapy (HAIC); later resection revealed pathological complete response. A 75-year-old man presented with HCC in his right liver, with tumor thrombosis growing to the right portal vein and the inferior vena cava, and bilateral intrahepatic liver metastases. He underwent HAIC (5-fluorouracil [170 mg/m HAIC can be an effective alternative treatment for advanced HCC with macrovascular invasion.

Sections du résumé

BACKGROUND BACKGROUND
Advanced hepatocellular carcinoma (HCC) with macrovascular invasion has an extremely dismal prognosis. We report a rare case of multiple HCC with tumor thrombosis in the portal vein and inferior vena cava that was initially treated with hepatic arterial infusion chemotherapy (HAIC); later resection revealed pathological complete response.
CASE PRESENTATION METHODS
A 75-year-old man presented with HCC in his right liver, with tumor thrombosis growing to the right portal vein and the inferior vena cava, and bilateral intrahepatic liver metastases. He underwent HAIC (5-fluorouracil [170 mg/m
CONCLUSIONS CONCLUSIONS
HAIC can be an effective alternative treatment for advanced HCC with macrovascular invasion.

Identifiants

pubmed: 31878937
doi: 10.1186/s12957-019-1772-8
pii: 10.1186/s12957-019-1772-8
pmc: PMC6933654
doi:

Substances chimiques

Cisplatin Q20Q21Q62J
Fluorouracil U3P01618RT

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

229

Références

Liver Cancer. 2015 Dec;4(4):228-40
pubmed: 26734578
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
J Clin Oncol. 2011 Apr 20;29(12):e330-2
pubmed: 21263091
World J Gastroenterol. 2016 Nov 14;22(42):9445-9450
pubmed: 27895433
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Case Rep Gastroenterol. 2015 Aug 06;9(2):285-90
pubmed: 26351418
Medicine (Baltimore). 2018 Oct;97(42):e12866
pubmed: 30334999
Hepatogastroenterology. 2007 Oct-Nov;54(79):2113-6
pubmed: 18251171
World J Gastroenterol. 2003 Dec;9(12):2666-70
pubmed: 14669309
Mol Clin Oncol. 2017 Dec;7(6):1013-1020
pubmed: 29285366
J Gastroenterol. 2012 Jun;47(6):686-95
pubmed: 22382631
Liver Cancer. 2017 Nov;6(4):275-286
pubmed: 29234631
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Drug Resist Updat. 2009 Jun;12(3):74-80
pubmed: 19394890
World J Gastroenterol. 2015 Feb 28;21(8):2568-72
pubmed: 25741170
Gut Liver. 2009 Dec;3(4):343-8
pubmed: 20431774
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432
pubmed: 29631810
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Hepatology. 1999 Jan;29(1):62-7
pubmed: 9862851
Clin J Gastroenterol. 2015 Oct;8(5):300-5
pubmed: 26249525
World J Gastroenterol. 2017 Jun 7;23(21):3797-3804
pubmed: 28638219
World J Surg Oncol. 2015 Apr 09;13:144
pubmed: 25889667
J Hepatol. 2012 Oct;57(4):821-9
pubmed: 22727733
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
World J Surg Oncol. 2013 Aug 02;11(1):171
pubmed: 23914915
Surg Case Rep. 2015;1(1):47
pubmed: 26366344
Cancer. 2002 Aug 1;95(3):588-95
pubmed: 12209752
Gut Liver. 2010 Jun;4(2):266-9
pubmed: 20559534
Br J Cancer. 2013 Oct 1;109(7):1904-7
pubmed: 24008659

Auteurs

Shusei Sano (S)

Department of Gastroenterological Surgery, Nagano Red Cross Hospital, 5-22-1, Wakasato, Nagano-shi, Nagano, 380-8582, Japan. sh.sano@nagano-med.jrc.or.jp.

Shinji Nakata (S)

Department of Gastroenterological Surgery, Nagano Red Cross Hospital, 5-22-1, Wakasato, Nagano-shi, Nagano, 380-8582, Japan.

Shuichi Wada (S)

Department of Gastroenterology, Nagano Red Cross Hospital, Nagano, Japan.

Masatsugu Kuroiwa (M)

Department of Gastroenterological Surgery, Nagano Red Cross Hospital, 5-22-1, Wakasato, Nagano-shi, Nagano, 380-8582, Japan.

Hiroki Sakai (H)

Department of Gastroenterological Surgery, Nagano Red Cross Hospital, 5-22-1, Wakasato, Nagano-shi, Nagano, 380-8582, Japan.

Kei Kusama (K)

Department of Gastroenterological Surgery, Nagano Red Cross Hospital, 5-22-1, Wakasato, Nagano-shi, Nagano, 380-8582, Japan.

Taiichi Machida (T)

Department of Gastroenterological Surgery, Nagano Red Cross Hospital, 5-22-1, Wakasato, Nagano-shi, Nagano, 380-8582, Japan.

Akihito Nishio (A)

Department of Gastroenterological Surgery, Nagano Red Cross Hospital, 5-22-1, Wakasato, Nagano-shi, Nagano, 380-8582, Japan.

Ichiro Ito (I)

Department of Pathology, Nagano Red Cross Hospital, Nagano, Japan.

Harutsugu Sodeyama (H)

Department of Gastroenterological Surgery, Nagano Red Cross Hospital, 5-22-1, Wakasato, Nagano-shi, Nagano, 380-8582, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH